Skip to main content
British Medical Journal logoLink to British Medical Journal
. 1974 Jul 13;3(5923):81–83. doi: 10.1136/bmj.3.5923.81

Myelosuppressive Effect of Colaspase (L-Asparaginase) in Initial Treatment of Acute Lymphoblastic Leukaemia

P G B Johnston, R M Hardisty, H E M Kay, P G Smith
PMCID: PMC1611087  PMID: 4604804

Abstract

Analysis of the remission induction phase in three Medical Research Council trials of treatment of acute lymphoblastic leukaemia has provided evidence of the adverse effect of the combination of colaspase (L-asparaginase) with vincristine and prednisolone. Significant myelosuppression, particularly of the granulocytic series, resulted in an increase in Gram-negative sepsis and death during the neutropenic phase induced by colaspase. The rate of blast-cell regression was increased by colaspase. It is suggested that the introduction of colaspase should be delayed until there is evidence of bone marrow regeneration in order to procure this benefit without the attendant toxicity.

Full text

PDF
83

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aur R. J., Simone J., Hustu H. O., Walters T., Borella L., Pratt C., Pinkel D. Central nervous system therapy and combination chemotherapy of childhood lymphocytic leukemia. Blood. 1971 Mar;37(3):272–281. [PubMed] [Google Scholar]
  2. Holland J. F., Glidewell O. Chemotherapy of acute lymphocytic leukemia of childhood. Cancer. 1972 Dec;30(6):1480–1487. doi: 10.1002/1097-0142(197212)30:6<1480::aid-cncr2820300611>3.0.co;2-3. [DOI] [PubMed] [Google Scholar]
  3. Land V. J., Sutow W. W., Fernbach D. J., Lane D. M., Williams T. E. Toxicity of L-asparginase in children with advanced leukemia. Cancer. 1972 Aug;30(2):339–347. doi: 10.1002/1097-0142(197208)30:2<339::aid-cncr2820300206>3.0.co;2-p. [DOI] [PubMed] [Google Scholar]
  4. Marai R., Guyonnet J. C., Julou L., De Ratuld Y., Werner G. H. Studies on the immunosuppressive activity of L-asparaginase. Recent Results Cancer Res. 1970;33:160–169. doi: 10.1007/978-3-642-99984-0_19. [DOI] [PubMed] [Google Scholar]
  5. Oettgen H. F., Tallal L., Tan C. C., Murphy M. L., Clarkson B. D., Golbey R. D., Krakoff I. H., Karnofsky D. A., Burchenal H. J. Clinical experience with L-asparaginase. Recent Results Cancer Res. 1970;33:219–235. doi: 10.1007/978-3-642-99984-0_27. [DOI] [PubMed] [Google Scholar]
  6. Pratt C. B., Johnson W. W. Duration and severity of fatty metamorphosis of the liver following L-asparaginase therapy. Cancer. 1971 Aug;28(2):361–364. doi: 10.1002/1097-0142(197108)28:2<361::aid-cncr2820280215>3.0.co;2-3. [DOI] [PubMed] [Google Scholar]
  7. Skeel R. T., Yankee R. A., Henderson E. S. Hexose monophosphate shunt activity of circulating phagocytes in acute lymphocytic leukemia. J Lab Clin Med. 1971 Jun;77(6):975–984. [PubMed] [Google Scholar]
  8. Strauss R. R., Paul B. B., Jacobs A. A., Simmons C., Sbarra A. J. The metabolic and phagocytic activities of leukocytes from children with acute leukemia. Cancer Res. 1970 Feb;30(2):480–488. [PubMed] [Google Scholar]

Articles from British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES